The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma
- PMID: 33754235
- DOI: 10.1007/s10637-021-01101-w
The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma
Abstract
Background To investigate the clinical efficiency of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) for advanced hepatocellular carcinoma (HCC). Methods This retrospective study enrolled 177 HCC patients, and they were divided into TACE monotherapy group (n = 129) and TACE + RFA group (n = 48) between January 2015 and October 2017. The objective response rate (ORR), disease control rate (DCR), and the survival outcomes were compared between the TACE monotherapy and the treatment of TACE + RFA after propensity score matching (PSM). Results After PSM matching, the confounding factors had no significant differences between the 48 pairs of patients. The DCR was calculated as 33 (69 %) and 42 (88 %) for the TACE monotherapy group and TACE + RFA group, respectively (P < 0.05). And the ORR was calculated as 23 (48 %) and 35 (73 %), respectively (P < 0.05). Moreover, the PFS rate of the TACE + RFA group was significantly higher than the TACE alone group (P < 0.001). Conclusions The treatment of TACE combined with RFA has better tumor response rate and survival rate than the TACE monotherapy for patients with advanced HCC.
Keywords: Hepatocellular carcinoma; Propensity score matching; Radiofrequency ablation; Transcatheter arterial chemoembolization.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.World J Surg Oncol. 2021 Mar 19;19(1):81. doi: 10.1186/s12957-021-02188-4. World J Surg Oncol. 2021. PMID: 33741001 Free PMC article. Review.
-
Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.J Cancer Res Clin Oncol. 2020 Oct;146(10):2669-2680. doi: 10.1007/s00432-020-03254-2. Epub 2020 May 25. J Cancer Res Clin Oncol. 2020. PMID: 32449005
-
Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis.Eur J Surg Oncol. 2020 May;46(5):763-771. doi: 10.1016/j.ejso.2020.01.004. Epub 2020 Jan 7. Eur J Surg Oncol. 2020. PMID: 31937433 Review.
-
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.BMC Cancer. 2019 Oct 22;19(1):983. doi: 10.1186/s12885-019-6237-5. BMC Cancer. 2019. PMID: 31640620 Free PMC article.
-
Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.Eur Radiol. 2018 Aug;28(8):3522-3531. doi: 10.1007/s00330-017-5166-4. Epub 2018 Mar 13. Eur Radiol. 2018. PMID: 29536241
Cited by
-
Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.Abdom Radiol (NY). 2024 Apr 20. doi: 10.1007/s00261-024-04277-w. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 38642094
-
Trans-radial versus trans-femoral approach for cerebral angiography: a meta-analysis of randomized controlled trials.Wideochir Inne Tech Maloinwazyjne. 2023 Jun;18(2):235-243. doi: 10.5114/wiitm.2022.123309. Epub 2022 Dec 22. Wideochir Inne Tech Maloinwazyjne. 2023. PMID: 37680739 Free PMC article.
-
Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C.World J Clin Cases. 2022 Nov 26;10(33):12156-12163. doi: 10.12998/wjcc.v10.i33.12156. World J Clin Cases. 2022. PMID: 36483812 Free PMC article.
-
Stent-based electrode for radiofrequency ablation in the rat esophagus: a preliminary study.Sci Rep. 2022 Nov 9;12(1):19135. doi: 10.1038/s41598-022-23472-7. Sci Rep. 2022. PMID: 36352051 Free PMC article.
-
MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.Cell Death Dis. 2022 Aug 20;13(8):727. doi: 10.1038/s41419-022-05180-2. Cell Death Dis. 2022. PMID: 35987690 Free PMC article.
References
-
- Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A, World Gastroenterology Organization (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245. https://doi.org/10.1097/MCG.0b013e3181d46ef2 - DOI - PubMed
-
- Mazzanti R, Gramantieri L, Bolondi L (2008) Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29:130–143. https://doi.org/10.1016/j.mam.2007.09.008 - DOI - PubMed
-
- Chen JG, Zhang SW (2011) Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 21:59–69. https://doi.org/10.1016/j.semcancer.2010.11.002 - DOI - PubMed
-
- Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. https://doi.org/10.1002/hep.24199 - DOI - PubMed
-
- Qin LX, Tang ZY (2002) The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 8:193–199. https://doi.org/10.3748/wjg.v24.i35.4000 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous